DR4 MEF（小鼠胚胎成纤维细胞）
CBP61134
询 价
索取STR
产品描述
产品数据库
| I. General information | |
| Synonyms: | DR4 MEF |
| Background: | The cell line was established by ATCC in 2003 from embryonic day 14 (E14) DR4 mouse embryos obtained from The Jackson Laboratory (Stock# 003208). Mouse embryo fibroblasts (MEFs) prepared from the DR4 mouse strain are resistant to neomycin, hygromycin, puromycin, and 6-thioguanine. Dr. Rudolf Jaenisch at the Massachusetts Institute of Technology developed the DR4 mouse strain by the intercrossing of three different strains: one bearing resistance genes neoR and puroR, a second bearing the resistance gene hygR, and a third bearing a natural deletion encompassing the Hprt gene. A series of matings incorporated all 4 drug resistance genes into the strain (Tucker et al., 1997; PubMed: 9278500). The background of the original DR4 strain was a mix of 129S4/SvJae, 129P2/OlaHsd, BALB/c, and C57BL/6. |
| Species: | Mus musculus, mouse |
| Tissue: | Embryo |
| Disease: | malignant histiocytosis |
| Gender: | Male and female mixed， 14 days gestation embryo |
| Morphology: | fibroblast |
| Growth Mode: | adherent |
| Doubling Time: | N/A |
| DNA Profile: | N/A Cobioer’s Cell Line Authentication Service |
| Culture Medium: |
DMEM+15%FBS DR4 MEF完全培养基，# CBP61134M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Antigen Expression: | N/A |
| Receptor Expression: | N/A |
| Oncogene: | N/A |
| Genes Expressed: | N/A |
| Cellular Products: | N/A |
| Tumor Formation: | N/A |
| Comments: | The growth of these cells should be arrested before being used as a feeder layer. ATCC has successfully irradiated and treated the cells with Mitomycin C for use as a feeder layer. If the MEFs are being used as a feeder layer for ES cells, it is not recommended to use them past passage no. 7 (P7). ATCC tested that this cell line is resistant to: G 418 (neomycin): 200 microgm/mL Puromycin: 0.4 microgm/mL Hygromycin: 110 microgm/mL 6-Thioguanine: 2.5 microgm/mL For more information, please contact Cobioer (4008-750-250). |
